Altium Capital Management LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 13, 2025), Altium Capital Management LLC reported 22 stock positions worth $34.4 million. Its top holding was Zevra Therapeutics (ZVRA) at 28.0% of the portfolio, followed by Evolus (EOLS, 10.3%) and Xtant Medical (XTNT, 9.9%). Compared with Q4 2024, it opened 4 new positions, sold out of 43 and reduced 17. The biggest buy was a new position in Intelligent Bio Solutions and the biggest sale an exit from Adma Biologics (ADMA).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001746382
- Portfolio Value
- $34.4M (Q1 2025)
- SEC Filing
- 0001420506-25-000988 ↗ filed May 13, 2025
Holdings Value
Holdings 22 stocks · $34.4M
| ZVRA Zevra Therapeutics Inc. | 28.00% | 1,287,333 | $9.6M | Reduce -30.4% |
| EOLS Evolus Inc. | 10.35% | 296,193 | $3.6M | Reduce -56.8% |
| XTNT Xtant Medical Holdings Inc. | 9.90% | 7,252,998 | $3.4M | Reduce -2.2% |
| AVDL Avadel Pharmaceuticals Ltd. | 9.53% | 419,131 | $3.3M | Reduce -7.4% |
| CTNM Contineum Therapeutics Inc. Class A | 6.16% | 303,857 | $2.1M | Reduce -9.0% |
| PROF Profound Medical Corp. | 6.09% | 360,589 | $2.1M | Reduce -25.6% |
| XENE Xenon Pharmaceuticals Inc. | 5.87% | 60,251 | $2.0M | Reduce -79.1% |
| EPIX Essa Pharma Inc. | 4.82% | 1,050,369 | $1.7M | Reduce -26.4% |
| SKYE Skye Bioscience Inc. | 4.18% | 904,865 | $1.4M | Reduce -20.6% |
| ACOG Alpha Cognition Inc. | 2.61% | 177,416 | $898K | Reduce -35.5% |
| RZLT Rezolute Inc. | 2.56% | 303,949 | $881K | Reduce -82.1% |
| NKTR Nektar Therapeutics | 2.08% | 1,051,379 | $715K | Reduce -65.0% |
| AVR Anteris Technologies Global | 1.78% | 168,589 | $614K | Reduce -77.1% |
| LRMR Larimar Therapeutics Inc. | 1.71% | 273,204 | $587K | Reduce -45.9% |
| PMN Promis Neurosciences Inc. | 1.16% | 574,248 | $399K | Reduce -1.2% |
| NVNO Envveno Medical Corporation | 0.94% | 123,256 | $324K | Reduce -60.2% |
| INTELLIGENT BIO SOLUTIONS IN | 0.62% | 149,252 | $215K | New |
| KPTI Karyopharm Therapeutics Inc. | 0.54% | 49,333 | $185K | No change |
| SHARPS TECHNOLOGY INC | 0.32% | 4,044,149 | $110K | New |
| LOGICMARK INC | 0.31% | 5,395,308 | $107K | New |
| SUNSHINE BIOPHARMA INC | 0.28% | 50,466 | $96K | New |
| SRXH SRX Global Inc. filed as BETTER CHOICE CO INC | 0.19% | 38,984 | $67K | Reduce -67.1% |
Options reported separately and not counted above: ALNY puts ($6.8M), XENE calls ($315K).
Portfolio Sells Q4 2024 → Q1 2025
| ADMA Adma Biologics Inc. | Sold out | 0.00% | −7.45 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −5.69 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −4.81 |
| ESTA Establishment Labs Holdings | Sold out | 0.00% | −4.38 |
| EW Edwards Lifesciences Corp. | Sold out | 0.00% | −3.80 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −3.50 |
| CAPR Capricor Therapeutics Inc. | Sold out | 0.00% | −3.07 |
| RXST Rxsight Inc. | Sold out | 0.00% | −3.05 |
| MMSI Merit Medical Systems Inc. | Sold out | 0.00% | −3.01 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −2.91 |
| INSM Insmed Inc. | Sold out | 0.00% | −2.84 |
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −1.95 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −1.92 |
| GKOS Glaukos Corp. | Sold out | 0.00% | −1.87 |
| RMD Resmed Inc. | Sold out | 0.00% | −1.85 |
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −1.83 |
| EXAS Exact Sciences Corp. | Sold out | 0.00% | −1.75 |
| LUNG Pulmonx Corp. | Sold out | 0.00% | −1.72 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −1.68 |
| CPRX Catalyst Pharmaceuticals Inc. | Sold out | 0.00% | −1.66 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −1.52 |
| SVRA Savara Inc. | Sold out | 0.00% | −1.51 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −1.41 |
| ARWR Arrowhead Pharmaceuticals Inc. | Sold out | 0.00% | −1.35 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −0.89 |
| TGTX TG Therapeutics Inc. | Sold out | 0.00% | −0.89 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −0.86 |
| IBRX Immunitybio Inc. | Sold out | 0.00% | −0.85 |
| LXEO Lexeo Therapeutics Inc. | Sold out | 0.00% | −0.83 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.82 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −0.82 |
| ATEC Alphatec Holdings Inc. | Sold out | 0.00% | −0.76 |
| OKUR Onkure Therapeutics Inc. Class A | Sold out | 0.00% | −0.58 |
| PRQR Proqr Therapeutics NV | Sold out | 0.00% | −0.47 |
| VERU Veru Inc. | Sold out | 0.00% | −0.41 |
| UNICYCIVE THERAPEUTICS INC | Sold out | 0.00% | −0.36 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −0.18 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| CTMX Cytomx Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.09 |
| ANAB Anaptysbio Inc. | Sold out | 0.00% | −0.08 |
| QUOIN PHARMACEUTICALS LTD | Sold out | 0.00% | −0.06 |
| RZLT Rezolute Inc. | Reduce -82.1% | 2.56% | −0.03 |
| CLRB Cellectar Biosciences Inc. | Sold out | 0.00% | −0.02 |
| SRXH SRX Global Inc. | Reduce -67.1% | 0.19% | +0.11 |
| AVR Anteris Technologies Global | Reduce -77.1% | 1.78% | +0.50 |
| NVNO Envveno Medical Corporation | Reduce -60.2% | 0.94% | +0.65 |
| PMN Promis Neurosciences Inc. | Reduce -1.2% | 1.16% | +0.99 |
| LRMR Larimar Therapeutics Inc. | Reduce -45.9% | 1.71% | +1.10 |
| NKTR Nektar Therapeutics | Reduce -65.0% | 2.08% | +1.21 |
Portfolio Buys Q4 2024 → Q1 2025
| INTELLIGENT BIO SOLUTIONS IN | New | 0.62% | +0.62 |
| SHARPS TECHNOLOGY INC | New | 0.32% | +0.32 |
| LOGICMARK INC | New | 0.31% | +0.31 |
| SUNSHINE BIOPHARMA INC | New | 0.28% | +0.28 |
Options Activity Q4 2024 → Q1 2025
| ESTA Establishment Labs Holdings | call | Sold out | 300,000 | $13.8Mbefore exit |
| SRRK Scholar Rock Holding Corp. | call | Sold out | 300,000 | $13.0Mbefore exit |
| ALNY Alnylam Pharmaceuticals Inc. | put | New | 25,000 | $6.8M |
| ANAB Anaptysbio Inc. | put | Sold out | 206,200 | $2.7Mbefore exit |
| LRMR Larimar Therapeutics Inc. | call | Sold out | 396,000 | $1.5Mbefore exit |
| APLT Applied Therapeutics Inc. | put | Sold out | 56,100 | $48Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $47.5M | RMT, ASA, RVT, NBXG, PDX |
| Q1 2026 | 19 | $42.0M | PDX, ASA, RVT, XPCQX, GAM |
| Q4 2025 | 18 | $25.3M | ASA, RVT, PDX, NBXG, XPCQX |
| Q3 2025 | 1 | $628K | CNSY |
| Q2 2025 | 0 | $0 | |
| Q1 2025Amended | 22 | $34.4M | ZVRA, EOLS, XTNT, AVDL, CTNM |
| Q4 2024 | 61 | $321.1M | ADMA, VERA, SRPT, ZVRA, ESTA |
| Q3 2024 | 57 | $334.9M | VERA, ADMA, SRPT, EW, XENE |
| Q2 2024 | 45 | $241.2M | VERA, ADMA, XENE, ITCI, SRPT |
| Q1 2024 | 46 | $222.3M | VERA, XENE, AXSM, ADMA, ALIM |